Anti-AIDS drug candidate and non-nucleoside reverse transcriptase inhibitor (NNRTI)
TMC125-R165335 (etravirine) caused an initial drop in viral load similar to that observed …

Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs) have
inherent flexibility, helping to maintain activity against a wide range of resistance mutations …

Drug resistance is a key cause of failure for treatment of HIV infection. The efficacy of non-
nucleoside reverse transcriptase inhibiting (NNRTI) drugs is impaired by rapid emergence of …

TMC278 is a diarylpyrimidine (DAPY) nonnucleoside reverse transcriptase inhibitor (NNRTI)
that is highly effective in treating wild-type and drug-resistant HIV-1 infections in clinical trials …

The structure for the complex of nonnucleoside inhibitor TMC125 and HIV-1 reverse
transcriptase has been determined and validated through computation of resistance profiles …

Abstract HIV-1 reverse transcriptase (RT) is a primary target for anti-AIDS drugs. Structures
of HIV-1 RT, usually determined at∼ 2.5–3.0 Å resolution, are important for understanding …

Currently, five NNRTIs have been approved by US Food and Drug Administration (US FDA)
for the clinical treatment of AIDS, ie, nevirapine, delavirdine, efavirenz, etravirine, and …

The selection of drug resistant virus is a significant obstacle to the continued successful
treatment of HIV infection. Reverse transcriptase is the target for numerous approved anti …

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are very potent and most
promising anti-AIDS drugs that specifically inhibit HIV-1 reverse transcriptase (RT) …

Owing to the emergence of resistant virus, next generation non-nucleoside HIV reverse
transcriptase inhibitors (NNRTIs) with improved drug resistance profiles have been …